Autologous CAR-T cell manufacturing has 2-10% failure rates resulting from contamination, operator error, and equipment failure in commercial settings . Autologous cell collection has a high cost and long manufacturing processes, delaying the availability of the treatment (4). In this context, allogeneic CAR-T cells offer certain advantages due to decreased cost and scale manufacturing ability. Allogeneic therapies allow for many cells to be harvested from the donor that are then cryopreserved, making treatments readily available for use and decreasing time to production (4). The systematic production of allogeneic T cells is expected to reduce cost and expand accessibility for CAR-T cell therapy (4). Autologous T cell collection can only be used to treat the donor patient, whereas allogeneic T cell manufacturing creates multiple batches of product for many patients (4). Allogeneic T cells can be injected again if the initial infusion is insufficient, which is especially crucial for patients whose disease recurs, necessitating a second dose. T cells taken from a patient who has undergone prior medical treatment may be limited in numbers, thus affecting initial administration doses and any reinfusion that may be necessary .